CARsgen Therapeutics Holdings Limited (HKG:2171)
Hong Kong
· Delayed Price · Currency is HKD 13.15
+0.73 (5.88%)
Jun 26, 2026, 4:08 PM HKT
CARsgen Therapeutics Holdings Employees
CARsgen Therapeutics Holdings had 355 employees as of December 31, 2025. The number of employees decreased by 110 or -23.66% compared to the previous year.
Employees
355
Change (1Y)
-110
Growth (1Y)
-23.66%
Revenue / Employee
393.91K HKD
Profits / Employee
-306.76K HKD
Market Cap
7.82B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 355 | -110 | -23.66% |
| Dec 31, 2024 | 465 | -51 | -9.88% |
| Dec 31, 2023 | 516 | -31 | -5.67% |
| Dec 31, 2022 | 547 | -26 | -4.54% |
| Dec 31, 2021 | 573 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Suzhou Ribo Life Science | 407 |
| Everest Medicines | 812 |
| CStone Pharmaceuticals | 136 |
| HBM Holdings | 272 |
| Shanghai Haohai Biological Technology | 2,110 |
| Abbisko Cayman | 276 |
| Alphamab Oncology | 498 |
| Lepu Biopharma | 710 |
CARsgen Therapeutics Holdings News
- 6 days ago - CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors - PRNewsWire
- 6 days ago - China approves CARsgen's CAR-T treatment to treat stomach cancer - Reuters
- 13 days ago - CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026 - PRNewsWire
- 27 days ago - Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting - PRNewsWire
- 4 months ago - CARsgen Therapeutics Announces 2025 Annual Results - PRNewsWire
- 4 months ago - CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai - PRNewsWire
- 5 months ago - CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors - PRNewsWire
- 5 months ago - Dispatch Bio and CARsgen Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors - Business Wire